Compare · ANIP vs ELOX
ANIP vs ELOX
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Eloxx Pharmaceuticals Inc. (ELOX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ANIP focuses on Biotechnology: Pharmaceutical Preparations, while ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ANIP is the larger of the two at $1.78B, about 321.3x ELOX ($5.5M).
- Over the past year, ANIP is up 21.1% and ELOX is up 15.2% - ANIP leads by 5.9 points.
- ANIP has hit the wire 8 times in the past 4 weeks while ELOX has been quiet.
- ANIP has more recent analyst coverage (12 ratings vs 4 for ELOX).
- Company
- ANI Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Inc.
- Price
- $79.27-3.21%
- $11.81+5.07%
- Market cap
- $1.78B
- $5.5M
- 1M return
- -4.54%
- -5.82%
- 1Y return
- +21.12%
- +15.22%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 12
- 4
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest ANIP
- SEC Form S-8 filed by ANI Pharmaceuticals Inc.
- Canaccord Genuity initiated coverage on ANI Pharma with a new price target
- ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $40,920 worth of shares (500 units at $81.84) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,390 units (SEC Form 4)
- ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
- SEC Form 144 filed by ANI Pharmaceuticals Inc.
- SVP & CFO Carey Stephen P. exercised 3,313 shares at a strike of $49.51 and sold $284,918 worth of shares (3,313 units at $86.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP & CFO Carey Stephen P. sold $239,742 worth of shares (2,850 units at $84.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 177,543 units (SEC Form 4)
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $41,015 worth of shares (500 units at $82.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,890 units (SEC Form 4)
- Director Thoma Jeanne was granted 4,357 shares, increasing direct ownership by 19% to 27,762 units (SEC Form 4)
Latest ELOX
- Large owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)
- New insider Domicilium Real Estate Fund Iii Lp claimed ownership of 14,285 shares (SEC Form 3)
- SEC Form 4 filed by Director Kjellson Nina S
- SEC Form 4 filed by Director Webster Stephen W
- SEC Form 4 filed by Director Walts Alan Edmund
- SEC Form 4 filed by Director Rubin Steven D
- SEC Form 4 filed by President and CEO Aggarwal Sumit
- SEC Form 424B4 filed by Eloxx Pharmaceuticals Inc.
- SEC Form EFFECT filed by Eloxx Pharmaceuticals Inc.
- Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq